The Role of Gut Microbiota in Acute Myeloid Leukemia
Authors:
- Lydia Maria InglezouLILydia Maria Inglezou
- Theocharis KonstantinidisTheocharis Konstantinidis
- Aikaterini SkevaASAikaterini Skeva
- Bouse MalkotsBMBouse Malkots
- Emmanouil PanagiotopoulosEPEmmanouil Panagiotopoulos
- Vasiliki SakkaVSVasiliki Sakka
- Emmanouil SpanoudakisESEmmanouil Spanoudakis
- Maria PanopoulouMaria Panopoulou
- Ioannis KotsianidisIKIoannis Kotsianidis
- Konstantinos LiapisKLKonstantinos Liapis
Open Access
- 7 May 2026
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (10) , 3571
Abstract
Gut microbiota plays a crucial role in regulating immune system function and shaping immunological responses to pathogens capable of causing infections. Alterations in the composition of the intestinal microbiome are associated with immune system dysfunction and increased susceptibility to infections. Patients with acute myeloid leukemia (AML) are highly susceptible to infections due to immune system deregulation caused by the disease itself, as well as chemotherapy-induced bone marrow aplasia. In these patients, gut microbiota dysbiosis and reduced microbial diversity (i.e., imbalances in the composition and function of intestinal microbes) result from multiple factors, including the underlying disease, neutropenia, dietary factors, use of antibiotics, chemotherapy regimens and prolonged hospitalization. Chemotherapy, for instance, induces damage to the intestinal mucosa and disrupts the epithelial barrier, resulting in deregulation of the intestinal microbiome. Previous studies have reported alterations in the human intestinal microbiome in patients with AML undergoing chemotherapy. Of particular interest is the capacity of some commensal bacteria to modulate the tumor microenvironment and response to chemotherapy. Moreover, increased mortality and reduced overall survival have been reported in patients who have undergone allogeneic stem cell transplantation and exhibit decreased gut microbiome diversity at the time of transplantation. These findings indicate that the composition of gut microbiota may play an important role in the prognosis of AML, especially in relation to therapeutic response. This narrative review summarizes new research into the role of the intestinal microbiome and the underlying alterations observed in patients with AML, resulting from the disease and therapeutic interventions and outlines strategies to improve its function and outcomes.Keywords
This publication has 74 references indexed in Scilit:
- Exploring Fecal Microbiota Transplantation: Potential Benefits, Associated Risks, and Challenges in Cancer TreatmentCancer Reports, 2026
- Sterile Diet Causes Gut Microbiome Collapse of Cancer Patients Post Hematopoietic Cell Transplantation, But Normal Diet Recovers ThemAdvanced Science, 2024
- Changes in the gut microbiota and risk of colonization by multidrug-resistant bacteria, infection, and death in critical care patientsClinical Microbiology and Infection, 2022
- Gut microbiota and short‐chain fatty acid alterations in cachectic cancer patientsJournal of Cachexia, Sarcopenia and Muscle, 2021
- Stopping antibiotic therapy after 72 h in patients with febrile neutropenia following intensive chemotherapy for AML/MDS (safe study): A retrospective comparative cohort studyeClinicalMedicine, 2021
- Gut microbiota and metabolic aspects of cancer cachexiaBest Practice & Research Clinical Endocrinology & Metabolism, 2021
- An insight into gut microbiota and its functionalitiesCellular and Molecular Life Sciences, 2018
- Experience with Saccharomyces boulardii Probiotic in Oncohaematological PatientsProbiotics and Antimicrobial Proteins, 2017
- Metagenomic Analysis of the Stool Microbiome in Patients Receiving Allogeneic Stem Cell Transplantation: Loss of Diversity Is Associated with Use of Systemic Antibiotics and More Pronounced in Gastrointestinal Graft-versus-Host DiseaseTransplantation and Cellular Therapy, 2014
- Questioning the Role of a Neutropenic Diet following Hematopoetic Stem Cell TransplantationTransplantation and Cellular Therapy, 2012